Business
Why the Immutep (ASX:IMM) share price is up 6% today
The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology company’s shares are up 5.97% to 36 cents.
New Phase 2b trial
The Immutep share price is on the move as investors have been rallying up on the positive news.
According to its release, Immutep advised that it has entered a second clinical trial collaboration and supply agreement with MSD. This will see Immutep commence a new Phase 2b trial, named TACTI-003 using first-line head and neck squamous cell carcinoma (HNSCC) patients.
HNSCC is an aggressive life-threatening cancer that affects either the…
-
General23 hours agoFrance calls for EU probe into Shein sex dolls, weapons
-
Noosa News17 hours agoEmerald house fire victims identified amid police probe
-
General13 hours agoQueensland considers allowing dingoes to be kept as pets
-
General20 hours agoInterest rate cuts might have less impact than thought